Who owns Vera Therapeutics, Inc. (OCRX)? Elite investor 13F holders
3 tracked elite investors reported holding Vera Therapeutics, Inc as of 2026-06-30, including Renaissance Technologies LLC, Alphabet, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | VERA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 11994546.00 USD | 279528.000000 | Shares | reduce | Original filing |
| Alphabet | VERA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-07 00:00:00 | 10352638.00 USD | 241264.000000 | Shares | hold | Original filing |
| D.E. Shaw | VERA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 3197182.00 USD | 74509.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.